SOFOCURE V is a fixed-dose combination of two direct-acting antiviral agents (DAAs) used for treating chronic hepatitis C virus (HCV) infection in adults.
Mechanism of action:
Inhibits viral replication
Blocks HCV RNA polymerase (sofosbuvir) and NS5A protein (velpatasvir)
Effective across all 6 genotypes
Recommended for:
Non-cirrhotic patients
Patients with compensated cirrhosis
Treatment-experienced patients
Treatment-naïve individuals
Chronic HCV infection (genotypes 1–6)
Patients with or without cirrhosis
Interferon-free therapy option
Take one tablet daily by mouth, with or without food. The typical course lasts 12 weeks, adjusted based on cirrhosis status and prior treatments. Therapy must be prescribed and monitored by a healthcare professional.
Hypersensitivity to any component
Severe hepatic impairment without medical supervision
Concomitant use with rifampicin, carbamazepine, phenytoin, or St. John’s wort
Headache
Fatigue
Nausea
Diarrhoea
Sleep disturbances
Elevated liver enzymes or bilirubin
